Literature DB >> 26133582

Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.

Jason M Williams1, Sudheer D Rani1, Xia Li1, Lori R Arlinghaus2, Tzu-Cheng Lee3, Lawrence R MacDonald4, Savannah C Partridge4, Hakmook Kang5, Jennifer G Whisenant1, Richard G Abramson1, Hannah M Linden6, Paul E Kinahan7, Thomas E Yankeelov8.   

Abstract

PURPOSE: Previous studies have demonstrated how imaging of the breast with patients lying prone using a supportive positioning device markedly facilitates longitudinal and/or multimodal image registration. In this contribution, the authors' primary objective was to determine if there are differences in the standardized uptake value (SUV) derived from [(18)F]fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) in breast tumors imaged in the standard supine position and in the prone position using a specialized positioning device.
METHODS: A custom positioning device was constructed to allow for breast scanning in the prone position. Rigid and nonrigid phantom studies evaluated differences in prone and supine PET. Clinical studies comprised 18F-FDG-PET of 34 patients with locally advanced breast cancer imaged in the prone position (with the custom support) followed by imaging in the supine position (without the support). Mean and maximum values (SUVpeak and SUVmax, respectively) were obtained from tumor regions-of-interest for both positions. Prone and supine SUV were linearly corrected to account for the differences in 18F-FDG uptake time. Correlation, Bland-Altman, and nonparametric analyses were performed on uptake time-corrected and uncorrected data.
RESULTS: SUV from the rigid PET breast phantom imaged in the prone position with the support device was 1.9% lower than without the support device. In the nonrigid PET breast phantom, prone SUV with the support device was 5.0% lower than supine SUV without the support device. In patients, the median (range) difference in uptake time between prone and supine scans was 16.4 min (13.4-30.9 min), which was significantly-but not completely-reduced by the linear correction method. SUVpeak and SUVmax from prone versus supine scans were highly correlated, with concordance correlation coefficients of 0.91 and 0.90, respectively. Prone SUVpeak and SUVmax were significantly lower than supine in both original and uptake time-adjusted data across a range of index times (P < < 0.0001, Wilcoxon signed rank test). Before correcting for uptake time differences, Bland-Altman analyses revealed proportional bias between prone and supine measurements (SUVpeak and SUVmax) that increased with higher levels of FDG uptake. After uptake time correction, this bias was significantly reduced (P < 0.01). Significant prone-supine differences, with regard to the spatial distribution of lesions relative to isocenter, were observed between the two scan positions, but this was poorly correlated with the residual (uptake time-corrected) prone-supine SUVpeak difference (P = 0.78).
CONCLUSIONS: Quantitative 18F-FDG-PET/CT of the breast in the prone position is not deleteriously affected by the support device but yields SUV that is consistently lower than those obtained in the standard supine position. SUV differences between scans arising from FDG uptake time differences can be substantially reduced, but not removed entirely, with the current correction method. SUV from the two scan orientations is quantitatively different and should not be assumed equivalent or interchangeable within the same subject. These findings have clinical relevance in that they underscore the importance of patient positioning while scanning as a clinical variable that must be accounted for with longitudinal PET measurement, for example, in the assessment of treatment response.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26133582      PMCID: PMC4464063          DOI: 10.1118/1.4921363

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  19 in total

1.  Optimizing imaging time for improved performance in oncology PET studies.

Authors:  Joseph A Thie; Karl F Hubner; Gary T Smith
Journal:  Mol Imaging Biol       Date:  2002-05       Impact factor: 3.488

2.  Time course of tumor SUV in 18F-FDG PET of breast cancer: presentation of a simple model using a single reference point for time corrections of tumor SUVs.

Authors:  Alexander R Stahl; Till A Heusner; Verena Hartung; James Nagarajah; Andreas Bockisch; Steffen Hahn; Gerald Antoch; Walter Jentzen
Journal:  J Nucl Med       Date:  2010-12-13       Impact factor: 10.057

3.  Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0.

Authors:  Dominique Delbeke; R Edward Coleman; Milton J Guiberteau; Manuel L Brown; Henry D Royal; Barry A Siegel; David W Townsend; Lincoln L Berland; J Anthony Parker; Karl Hubner; Michael G Stabin; George Zubal; Marc Kachelriess; Valerie Cronin; Scott Holbrook
Journal:  J Nucl Med       Date:  2006-05       Impact factor: 10.057

4.  Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

Authors:  Lalitha K Shankar; John M Hoffman; Steve Bacharach; Michael M Graham; Joel Karp; Adriaan A Lammertsma; Steven Larson; David A Mankoff; Barry A Siegel; Annick Van den Abbeele; Jeffrey Yap; Daniel Sullivan
Journal:  J Nucl Med       Date:  2006-06       Impact factor: 10.057

5.  Longitudinal, intermodality registration of quantitative breast PET and MRI data acquired before and during neoadjuvant chemotherapy: preliminary results.

Authors:  Nkiruka C Atuegwu; Xia Li; Lori R Arlinghaus; Richard G Abramson; Jason M Williams; A Bapsi Chakravarthy; Vandana G Abramson; Thomas E Yankeelov
Journal:  Med Phys       Date:  2014-05       Impact factor: 4.071

6.  A concordance correlation coefficient to evaluate reproducibility.

Authors:  L I Lin
Journal:  Biometrics       Date:  1989-03       Impact factor: 2.571

7.  Quantitative FDG PET/CT in the community: experience from interpretation of outside oncologic PET/CT exams in referred cancer patients.

Authors:  Abdel K Tahari; Richard L Wahl
Journal:  J Med Imaging Radiat Oncol       Date:  2013-12-03       Impact factor: 1.735

Review 8.  From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Authors:  Richard L Wahl; Heather Jacene; Yvette Kasamon; Martin A Lodge
Journal:  J Nucl Med       Date:  2009-05       Impact factor: 10.057

Review 9.  Review of imaging techniques for the diagnosis of breast cancer: a new role of prone scintimammography using technetium-99m sestamibi.

Authors:  I Khalkhali; I Mena; L Diggles
Journal:  Eur J Nucl Med       Date:  1994-04

10.  Correction of scan time dependence of standard uptake values in oncological PET.

Authors:  Jörg van den Hoff; Alexandr Lougovski; Georg Schramm; Jens Maus; Liane Oehme; Jan Petr; Bettina Beuthien-Baumann; Jörg Kotzerke; Frank Hofheinz
Journal:  EJNMMI Res       Date:  2014-04-03       Impact factor: 3.138

View more
  3 in total

1.  Towards real-time topical detection and characterization of FDG dose infiltration prior to PET imaging.

Authors:  Jason M Williams; Lori R Arlinghaus; Sudheer D Rani; Martha D Shone; Vandana G Abramson; Praveen Pendyala; A Bapsi Chakravarthy; William J Gorge; Joshua G Knowland; Ronald K Lattanze; Steven R Perrin; Charles W Scarantino; David W Townsend; Richard G Abramson; Thomas E Yankeelov
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-25       Impact factor: 9.236

2.  Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer.

Authors:  Angela M Jarrett; David A Hormuth; Vikram Adhikarla; Prativa Sahoo; Daniel Abler; Lusine Tumyan; Daniel Schmolze; Joanne Mortimer; Russell C Rockne; Thomas E Yankeelov
Journal:  Sci Rep       Date:  2020-11-25       Impact factor: 4.379

3.  Quantitative Comparison of Prone and Supine PERCIST Measurements in Breast Cancer.

Authors:  Jennifer G Whisenant; Jason M Williams; Hakmook Kang; Lori R Arlinghaus; Richard G Abramson; Vandana G Abramson; Kareem Fakhoury; A Bapsi Chakravarthy; Thomas E Yankeelov
Journal:  Tomography       Date:  2020-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.